Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany

Clinical Research in Cardiology

Volumn 99, Issue 11, 2010, Pages 723-733

  Gitt, Anselm K ^a,b   Jünger, Claus ^a   Smolka, Wenefrieda ^c   Bestehorn, Kurt ^c,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KLINIKUM LUDWIGSHAFEN   (Germany)

^c MSD Sharp and Dohme GmbH   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dyslipidemia; High density lipoprotein cholesterol; Primary care; Statins; Treatment targets

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE PLUS SIMVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL; DYSLIPIDEMIA; FEMALE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK FACTOR;

AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 78649664457     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0177-z     Document Type: Article

References (51)

1. F Levi L Chatenoud P Bertuccio F Lucchini E Negri CL Vecchia 2009 Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update Eur J Cardiovasc Prev Rehabil 16 3 333 350 10.1097/HJR.0b013e328325d67d 19369880 (epub ahead of print)
2. T Rodriguez M Malvezzi L Chatenoud C Bosetti F Levi E Negri C La Vecchia 2006 Trends in mortality from coronary heart and cerebrovascular diseases in the Americas: 1970-2000 Heart 92 4 453 460 1:STN:280:DC%2BD287kvVCgtQ%3D%3D 10.1136/hrt.2004.059295 16537758
3. U Zeymer KG Parhofer D Pittrow C Binz M Schwertfeger T Limbourg J Rother 2009 Risk factor profile, management and prognosis of patients with peripheral arterial disease with or without coronary artery disease: results of the prospective German REACH registry cohort Clin Res Cardiol 98 4 249 256 10.1007/s00392-009-0754-1 19221687
4. AG Mainous 3rd R Baker RJ Koopman S Saxena VA Diaz CJ Everett A Majeed 2007 Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way Diabetologia 50 5 934 940 10.1007/s00125-006-0528-5 17119914 (Pubitemid 46559242)
5. S Haffner H Taegtmeyer 2003 Epidemic obesity and the metabolic syndrome Circulation 108 13 1541 1545 10.1161/01.CIR.0000088845.17586.EC 14517149 (Pubitemid 37187777)
6. American Diabetes Association (ADA) 2004 Dyslipidemia management in adults with diabetes Diabetes Care 27 90001 S68 S71 10.2337/diacare.27.2007.S68
7. V Snow MD Aronson ER Hornbake C Mottur-Pilson KB Weiss 2004 Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians Ann Intern Med 140 8 644 649 15096336
8. S Yusuf S Hawken S Ounpuu T Dans A Avezum F Lanas M McQueen A Budaj P Pais J Varigos L Lisheng 2004 Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study Lancet 364 9438 937 952 10.1016/S0140-6736(04)17018-9 15364185 (Pubitemid 39208455)
9. J Muller-Nordhorn H Englert K Wegscheider H Berger F Sonntag H Voller W Meyer-Sabellek T Reinhold E Windler HA Katus SN Willich 2008 Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany Clin Res Cardiol 97 3 152 159 10.1007/s00392-007-0602-0 18060377 (Pubitemid 351712811)
10. JD Brunzell M Davidson CD Furberg RB Goldberg BV Howard JH Stein JL Witztum 2008 Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation J Am Coll Cardiol 51 15 1512 1524 10.1016/j.jacc.2008.02.034 18402913 (Pubitemid 351470037)
11. C Baigent A Keech PM Kearney L Blackwell G Buck C Pollicino A Kirby T Sourjina R Peto R Collins R Simes 2005 Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 366 9493 1267 1278 1:CAS:528:DC%2BD2MXhtVOlu7fM 10.1016/S0140-6736(05)67394-1 16214597 (Pubitemid 41416582)
12. MR Law NJ Wald AR Rudnicka 2003 Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis Brit Med J 326 7404 1423 1430 1:CAS:528: DC%2BD3sXlvFCjsLY%3D 10.1136/bmj.326.7404.1423 12829554
13. JMS Lee RP Choudhury 2007 Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets Heart 93 5 559 564 1:CAS:528:DC%2BD2sXls12ktb0%3D 10.1136/hrt.2005. 066050 16449520 (Pubitemid 46707106)
14. Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults 2001 Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 19 2486 2497 10.1001/jama.285.19.2486
15. E Bruckert M Baccara-Dinet F McCoy J Chapman 2005 High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients Curr Med Res Opin 21 12 1927 1934 1:CAS:528:DC%2BD28XhtF2jurY%3D 10.1185/030079905X74871 16368042 (Pubitemid 41803102)
16. E Van Ganse L Laforest T Burke H Phatak T Souchet 2007 Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study Clin Ther 29 8 1671 1681 10.1016/j.clinthera.2007.08.003 17919548 (Pubitemid 47500127)
17. PW Connelly A Petrasovits S Stachenko DR MacLean JA Little A Chockalingam 1999 Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group Can J Cardiol 15 4 428 433 1:STN:280:DyaK1M3lslCnsw%3D%3D 10322252
18. RW Grant JB Meigs 2007 Prevalence and treatment of low HDL cholesterol among primary care patients with type 2 diabetes: an unmet challenge for cardiovascular risk reduction Diabetes Care 30 3 479 484 1:CAS:528: DC%2BD2sXjs1GrtL0%3D 10.2337/dc06-1961 17327308 (Pubitemid 46354321)
19. P Primatesta NR Poulter 2006 Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003 Clin Endocrinol (Oxf) 64 3 292 298 10.1111/j.1365-2265.2006.02459.x
20. DC Goff Jr AG Bertoni H Kramer D Bonds RS Blumenthal MY Tsai BM Psaty 2006 Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium Circulation 113 5 647 656 1:CAS:528:DC%2BD28XovVCgtA%3D%3D 10.1161/ CIRCULATIONAHA.105.552737 16461837
21. DJ Magliano JE Shaw PZ Zimmet 2006 How to best define the metabolic syndrome Ann Med 38 1 34 41 1:CAS:528:DC%2BD28XhtVGnsbk%3D 10.1080/ 07853890500300311 16448987 (Pubitemid 43177786)
22. RM Conroy K Pyorala AP Fitzgerald S Sans A Menotti G De Backer D De Bacquer P Ducimetiere P Jousilahti U Keil I Njolstad RG Oganov T Thomsen H Tunstall-Pedoe A Tverdal H Wedel P Whincup L Wilhelmsen IM Graham 2003 Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 11 987 1003 1:STN:280:DC%2BD3s3mtFGnuw%3D%3D 10.1016/S0195-668X(03)00114-3 12788299 (Pubitemid 36712275)
23. I Graham D Atar K Borch-Johnsen G Boysen G Burell R Cifkova J Dallongeville G De Backer S Ebrahim B Gjelsvik C Herrmann-Lingen A Hoes S Humphries M Knapton J Perk SG Priori K Pyorala Z Reiner L Ruilope S Sans-Menendez W Scholte op Reimer P Weissberg D Wood J Yarnell JL Zamorano E Walma T Fitzgerald MT Cooney A Dudina A Vahanian J Camm R De Caterina V Dean K Dickstein C Funck-Brentano G Filippatos I Hellemans SD Kristensen K McGregor U Sechtem S Silber M Tendera P Widimsky JL Zamorano I Hellemans A Altiner E Bonora PN Durrington R Fagard S Giampaoli H Hemingway J Hakansson SE Kjeldsen ML Larsen G Mancia AJ Manolis K Orth-Gomer T Pedersen M Rayner L Ryden M Sammut N Schneiderman AF Stalenhoef L Tokgozoglu O Wiklund A Zampelas 2007 European guidelines on cardiovascular disease prevention in clinical practice: executive summary Eur Heart J 28 19 2375 2414 10.1093/eurheartj/ehm316 17726041 (Pubitemid 47542237)
24. WC Roberts 1997 The rule of 5 and the rule of 7 in lipid-lowering by statin drugs Am J Cardiol 80 1 106 107 1:STN:280:DyaK2szkvFSgsA%3D%3D 10.1016/S0002-9149(97)00298-1 9205036 (Pubitemid 27274595)
25. RH Knopp 1999 Drug treatment of lipid disorders N Engl J Med 341 7 498 511 1:STN:280:DyaK1MzltlGjtQ%3D%3D 10.1056/NEJM199908123410707 10441607 (Pubitemid 29372891)
26. GA Nichols S Nag W Chan 2007 Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update Am Heart J 154 3 554 560 10.1016/j.ahj.2007.04.037 17719305 (Pubitemid 47277443)
27. G Assmann H Benecke A Neiss P Cullen H Schulte K Bestehorn 2006 Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy calculation and measurement of cardiovascular and cerebrovascular events including physicians' experience and evaluation) Eur J Cardiovasc Prev Rehabil 13 5 776 783 10.1097/01.hjr.0000189805.76482.6e 17001218 (Pubitemid 44454851)
28. SD Persell DM Lloyd-Jones DW Baker 2006 Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia J Gen Intern Med 21 2 171 176 16390501
29. L Ose FE Skjeldestad IJ Bakken A Levorsen EA Alemao DD Yin F Borgstrom L Jonsson 2006 Lipid management and cholesterol goal attainment in Norway Am J Cardiovasc Drugs 6 2 121 128 1:CAS:528:DC%2BD28XlvVSqu7c%3D 10.2165/00129784- 200606020-00006 16555865
30. Ghandehari H, Le H, Ambegaonkar B, Sazonov V, Wong N (2008). Abstract 3704: prevalence of lipid disorders and treatment patterns in overall and high risk US adults with dyslipidemia in 2003-2004. Circulation 118 (18-MeetingAbstracts):S-470-c
31. NCEP ATP III guidelines at-a-glance quick desk reference. Available at http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf. Accessed on 21 July 2009
32. SM Grundy JI Cleeman CN Merz HB Brewer Jr LT Clark DB Hunninghake RC Pasternak SC Smith Jr NJ Stone 2004 Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2 227 239 10.1161/01.CIR.0000133317.49796.0E 15249516 (Pubitemid 38924592)
33. RW Grant E Cagliero AK Dubey C Gildesgame HC Chueh MJ Barry DE Singer DM Nathan JB Meigs 2004 Clinical inertia in the management of type 2 diabetes metabolic risk factors Diabet Med 21 2 150 155 1:STN:280: DC%2BD2c%2FpsFarsg%3D%3D 10.1111/j.1464-5491.2004.01095.x 14984450 (Pubitemid 38221814)
34. BR Shah JE Hux PC Austin 2007 Diabetes is not treated as a coronary artery disease risk equivalent Diabetes Care 30 2 381 383 10.2337/dc06-1654 17259516 (Pubitemid 46198352)
35. WP Castelli RJ Garrison PW Wilson RD Abbott S Kalousdian WB Kannel 1986 Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA 256 20 2835 2838 1:STN:280:DyaL2s%2FjslWktA%3D%3D 10.1001/jama.256.20.2835 3773200 (Pubitemid 17178361)
36. AR Sharrett CM Ballantyne SA Coady G Heiss PD Sorlie D Catellier W Patsch 2001 Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 10 1108 1113 1:CAS:528:DC%2BD3MXotlWgur0%3D 10.1161/hc3501.095214 11535564
37. MJ Stampfer FM Sacks S Salvini WC Willett CH Hennekens 1991 A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction N Engl J Med 325 6 373 381 1:STN:280:DyaK3M3oslOntw%3D%3D 10.1056/ NEJM199108083250601 2062328
38. G Assmann H Schulte 1992 Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study Am J Cardiol 70 7 733 737 1:STN:280:DyaK38zptFersg%3D%3D 10.1016/0002-9149(92)90550-I 1519522
39. G Assmann H Schulte A von Eckardstein Y Huang 1996 High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 Suppl S11 S20 1:CAS:528:DyaK28XjvFGqtb4%3D 10.1016/0021-9150(96)05852-2 8831911 (Pubitemid 26268441)
40. S Wild CD Byrne 2008 Time to rethink high-density lipoprotein? Heart 94 6 692 694 1:CAS:528:DC%2BD1cXnsFGhtb0%3D 10.1136/hrt.2007.126326 18480346 (Pubitemid 351744684)
41. JK Ninomiya G L'Italien MH Criqui JL Whyte A Gamst RS Chen 2004 Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey Circulation 109 1 42 46 10.1161/01.CIR.0000108926.04022.0C 14676144 (Pubitemid 38056019)
42. AA Alsheikh-Ali JL Lin P Abourjaily D Ahearn JT Kuvin RH Karas 2007 Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol Am J Cardiol 100 10 1499 1501 1:CAS:528: DC%2BD2sXht12ns7nI 10.1016/j.amjcard.2007.06.058 17996508 (Pubitemid 350050854)
43. AK Gitt C Juenger C Jannowitz B Karmann J Senges K Bestehorn 2009 Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry Eur J Cardiovasc Prev Rehabil 16 4 438 444 10.1097/HJR.0b013e32832a4e25 19369876
44. Häussler B, Höer A, Hempel E, Klein S Arzneimittelatlas (2009) Der Arzneimittelverbrauch in der GKV. Lipidsenkende Mittel. Urban und Vogel, München, pp 147
45. AT Yan RT Yan M Tan DG Hackam KL Leblanc H Kertland JL Tsang S Jaffer ML Kates LA Leiter DH Fitchett A Langer SG Goodman 2006 Contemporary management of dyslipidemia in high-risk patients: targets still not met Am J Med 119 8 676 683 10.1016/j.amjmed.2005.11.015 16887414 (Pubitemid 44128440)
46. TA Pearson I Laurora H Chu S Kafonek 2000 The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals Arch Intern Med 160 4 459 467 1:CAS:528:DC%2BD3cXhvFGhur8%3D 10.1001/archinte.160.4.459 10695686
47. L Mosca NB Merz RS Blumenthal MJ Cziraky RP Fabunmi C Sarawate KE Watson VJ Willey EJ Stanek 2005 Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting Circulation 111 4 488 493 10.1161/01.CIR.0000153859.66086.85 15687138 (Pubitemid 40204434)
48. MH Davidson KC Maki TA Pearson RC Pasternak PC Deedwania JM McKenney GC Fonarow DJ Maron BJ Ansell LT Clark CM Ballantyne 2005 Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations Am J Cardiol 96 4 556 563 10.1016/j.amjcard.2005.04.019 16098311 (Pubitemid 41132774)
49. JS Alpert 2000 Are data from clinical registries of any value? Eur Heart J 21 17 1399 1401 1:STN:280:DC%2BD3M%2Fis12msA%3D%3D 10.1053/euhj.2000.2265 10952831 (Pubitemid 30636318)
50. EL Knight RL Bohn PS Wang RJ Glynn H Mogun J Avorn 2001 Predictors of uncontrolled hypertension in ambulatory patients Hypertension 38 4 809 814 1:CAS:528:DC%2BD3MXotVChs7Y%3D 10.1161/hy0901.091681 11641291
51. K Bestehorn K Wegscheider H Voller 2008 Contemporary trends in cardiac rehabilitation in Germany: patient characteristics, drug treatment, risk-factor management from 2000 to 2005 Eur J Cardiovasc Prev Rehabil 15 3 312 318 10.1097/HJR.0b013e3282f40e14 18525386